XENE · Xenon Pharmaceuticals Inc. · Webcasts, Transcripts & Audio
$40.48
-0.52 (-1.26%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.98B
Shares
98.28M
Volume · Nov 13
607.68K
Avg daily vol (3M)
1.62M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Xenon Pharmaceuticals Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Xenon Pharmaceuticals Inc. (XENE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-01
Xenon Pharmaceuticals Inc. (XENE) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Xenon Pharmaceuticals Inc. (XENE) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-11
Xenon Pharmaceuticals Inc. (XENE) November 11, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Xenon Pharmaceuticals Inc. (XENE) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-09
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Confident tone
NAV 1.7 and KV7 pain programs
AZK regulatory submission and launch preparation
Neuropsychiatry data and development pause
Revenue
$0
Diluted EPS
$-1.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Xenon Pharmaceuticals Inc. (XENE) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Confident tone
Pain pipeline (KV7 and Nav1.7)
AZK NDA submission and launch readiness for focal seizures
XTOL2 Phase 3 efficacy data and medical education
Revenue
$0
Diluted EPS
$-1.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Xenon Pharmaceuticals Inc. (XENE) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Xenon Pharmaceuticals Inc. (XENE) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-14
Xenon Pharmaceuticals Inc. (XENE) May 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Confident tone
AZK Phase 3 EXTOL-2 data and epilepsy
Early-stage pipeline: pain and Dravet
Commercial readiness and launch planning
Revenue
$0
▼ 100% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-22
Xenon Pharmaceuticals Inc. (XENE) April 22, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-09
Xenon Pharmaceuticals Inc. (XENE) Q4 2025 Earnings Call
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
Confident tone
Azetukalner differentiation and commercial profile
X-TOLE2 Phase III readout in focal onset seizures
Earlier-stage ion channel programs (Nav1.7, Kv7, Nav1.1)
Revenue
$0
Diluted EPS
$-1.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
Confident tone
Azetukalner Phase III X-TOLE2 in focal onset seizures
Earlier-stage Nav1.1, Nav1.7 and Kv7 pipeline
Major depressive disorder (MDD) Phase III program
Revenue
$0
Diluted EPS
$-1.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript
Positive tone
Azetukalner Phase 3 epilepsy (X-TOLE2)
Investigator-led MDD study results
Azetukalner in MDD and bipolar depression
Revenue
$7.50M
Diluted EPS
$-0.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Confident tone
Phase 3 epilepsy readout / azetukalner
MDD (major depressive disorder) program
Bipolar depression program
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
Confident tone
Azetukalner epilepsy program (X-TOLE)
Nav1.7 pain program
MDD program (X-NOVA)
Revenue
$0
Diluted EPS
$-0.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Xenon Pharmaceuticals Inc. (XENE) Q2 2024 Earnings Call Transcript
Confident tone
Phase 3 azetukalner epilepsy program execution
Nav1.7 sodium channel pain program
X-ACKT primary generalized tonic-clonic seizure study
Revenue
$0
Diluted EPS
$-0.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Xenon Pharmaceuticals Inc. (XENE) Q1 2024 Earnings Call Transcript
Confident tone
Azetukalner (XEN1101) INN naming milestone
Phase III epilepsy program (X-TOLE2, X-TOLE3, X-ACKT)
Kv7 pipeline and discovery portfolio
Revenue
$0
Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript
Confident tone
XEN1101 Phase 3 Epilepsy Program (X-TOLE2/X-TOLE3/X-ACKT)
MDD Development / X-NOVA Results
FDA End-of-Phase 2 Meeting
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Xenon Pharmaceuticals Inc. (XENE) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.72
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Xenon Pharmaceuticals Inc. (XENE) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Xenon Pharmaceuticals Inc. (XENE) Q4 2022 Earnings Call Transcript
Revenue
$0*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Xenon Pharmaceuticals Inc. (XENE) Q3 2022 Earnings Call Transcript
Revenue
$132,000
▼ 98.4% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Xenon Pharmaceuticals Inc. (XENE) Q2 2022 Earnings Call Transcript
Revenue
$536,000
▼ 75.8% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Xenon Pharmaceuticals Inc. (XENE) Q1 2022 Earnings Call Transcript
Revenue
$8.77M
▲ 101.1% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Xenon Pharmaceuticals Inc. (XENE) Q4 2021 Earnings Call Transcript
Revenue
$3.74M*
▼ 27.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Xenon Pharmaceuticals Inc. (XENE) Q3 2021 Earnings Call Transcript
Revenue
$8.12M
▲ 24% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Xenon Pharmaceuticals Inc. (XENE) Q2 2021 Earnings Call Transcript
Revenue
$2.22M
▼ 83.4% YoY Diluted EPS
$-0.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Xenon Pharmaceuticals Inc. (XENE) Q1 2021 Earnings Call Transcript
Revenue
$4.36M
▼ 38.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Xenon Pharmaceuticals Inc. (XENE) Q4 2020 Earnings Call Transcript
Revenue
$5.15M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Xenon Pharmaceuticals Inc. (XENE) Q3 2020 Earnings Call Transcript
Revenue
$6.55M
▲ 87.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Xenon Pharmaceuticals Inc. (XENE) Q2 2020 Earnings Call Transcript
Revenue
$13.38M
Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-21
Xenon Pharmaceuticals Inc. (XENE) Q1 2020 Earnings Call Transcript
Revenue
$7.08M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-09
Xenon Pharmaceuticals Inc. (XENE) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–37 of 37 webcasts
Key facts
CIK
1582313
CUSIP
98420N105
13F (30d)
230 filings
192 filers
Visit website
Investor relations